AstraZeneca Shares Surge 3% on CDSCO Approval for Cancer Drug

Shares of AstraZeneca Pharma India Ltd surged 3% on 10 February after the company announced that it had acquired clearance from the Central Drugs Standard Control Organisation (CDSCO) to import Imfinzi (durvalumab) solution, which is used to treat endometrial cancer.

In an exchange filing, the pharmaceutical company stated that the Central Drugs Standard Control Organisation approved the import, sale, and distribution of durvalumab solution for infusion 120mg/2.4ml and 500mg/10mL.

“Through this approval, durvalumab in combination with carboplatin and paclitaxel is indicated for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with Durvalumab as monotherapy in endometrial cancer that is mismatch repair-deficient (dMMR),” the company said in an exchange filing.

The approval allows for the sale of durvalumab solution for infusion 120mg/2.4ml and 500mg/10ml (Imfinzi) in India for the indicated new indication, subject to the receipt of any necessary legislative approvals, it added.

Last month, the pharma company gained CDSCO approval for Imfinzi or durvalumab solution, which is approved for the treatment of adult patients with resectable stomach or gastroesophageal junction adenocarcinoma.

At 3:01 pm, the shares of AstraZeneca were trading 2.98% higher at Rs 8,933 on NSE.

Discover the next big investment! Tradz by EquityPandits’ IPO screener helps you identify promising initial public offerings. Download Tradz by EquityPandit and get ahead of the curve! Sign Up Now & Find Your Next IPO Gem!

The post AstraZeneca Shares Surge 3% on CDSCO Approval for Cancer Drug appeared first on Equitypandit.